Nephew, Lauren D.2021-10-202021-10-202021-06-01Nephew, L. D. (2021). Accountability in clinical trial diversity: The buck stops where? EClinicalMedicine, 36. https://doi.org/10.1016/j.eclinm.2021.1009062589-5370https://hdl.handle.net/1805/26821If the Pfizer and Moderna Coronavirus Disease (COVID-19) studies taught us one thing, it is that clinical trials can better reflect the diverse demographics of the population. Why then, do not most other Phase 3 clinical trials account for the diversity of the population who will most likely use the drug? Most do not, because there is no accountability. In developing the COVID-19 vaccine, industry and its partners were well aware of their mandate: develop a vaccine quickly that would be acceptable and legitimate to the public.enAttribution-NonCommercial-NoDerivatives 4.0 InternationalClinical Trial DiversitypfizermodernaCOVID 19Article